摘要：It is well known that the number of people with Tuberculosis (TB) and those who develop multidrug resistance (MDR) are the fundamental components that affect the total cost of treatment of TB. This paper has two-fold objectives. Firstly, we use the Generalized Linear Regression Models (GLM) to predict the future count of persons with TB and MDR. Due to the fact that assessment of TB cost is methodologically difficult, and compounded with the lack of concrete information about the treatment cost in Saudi Arabia, our second objective is to use cost information from the EU countries as proxy to estimate the cost of treating TB. The cost predictions provide essential information that is part of the evidence needed for budgeting and financing the health care facilities of TB services, especially with respect to avoiding under-estimation of the cost of TB-MDR treatment.
